Skip to content
Business Company News, Medical Health Aged Care

The Hon Gabrielle Upton joins the Florey Board

- 2 mins read

The Florey is pleased to announce the appointment of the Hon Gabrielle Upton to its Board of Directors. 

Ms Upton has had a distinguished career as a lawyer, banker, government minister and university Deputy Chancellor. 

She was New South Wales’ first female Attorney General, is a Board Member of Netball Australia, and serves as an Advisory Board Member of the Australian Research Council Centre of Excellence of Quantum Biotechnology.  

The Florey’s Board Chair, Mr Martin Adams, welcomed Ms Upton to the Board.   

“Gabrielle is a leader who brings a wealth of experience to The Florey. She has extensive knowledge of medical research, neuroscience and higher education, having previously served on the board of Neuroscience Research Australia (NeuRA) and as Deputy Chancellor of the University of New South Wales,” Mr Adams said. 

“The Florey is building momentum, working at the frontier of neuroscience and mental health. Our work is transforming lives and communities here in Australia and around the world. It’s an exciting time for Gabrielle to be joining the Florey, and we are delighted to have her as a member of the Board. 

Ms Upton said she was excited to join The Florey board.  

“The Florey has a distinguished history and bright future finding the causes and cures for diseases affecting the brain – the least understood part of our body. I particularly look forward to supporting its work to improve the lives of people living with brain and mental health conditions,” she said.

 


About us:

The Florey is Australia’s leading brain research institute with a focus on improving the lives of people with neurological and psychiatric conditions. The Florey’s research missions are centred around dementiaepilepsymental health and developing ways to protect and repair the brain. These missions are strengthened by The Florey’s expertise in neurotherapeutics, neuroimaging, synaptic biology and systems neuroscience. With 600 researchers, The Florey is the largest research centre of its kind in the southern hemisphere.

Find out more about us on our website: www.florey.edu.au


Contact details:

Kathryn Powley, Media and Communications Manager

kathryn.powley@florey.edu.au | 0456 666 271

Media

More from this category

  • Medical Health Aged Care
  • 31/10/2024
  • 17:55
Kyowa Kirin Co., Ltd.

Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company’s 2030…

  • Contains:
  • Business Company News, Government VIC
  • 31/10/2024
  • 16:00
Victorian Small Business Commission

Growing number of small businesses in dispute over unpaid money: VSBC Annual Report 2023-24

Almost half (41%) of dispute resolution applications to the Victorian Small Business Commission (VSBC) under the Small Business Commission Act were related to unpaid money, according to its Annual Report 2023-24, tabled in parliament today. The VSBC is an independent statutory authority tasked with preventing and resolving disputes faced by small businesses, retail tenants and their landlords. Victorian Small Business Commissioner Lynda McAlary-Smith said this was a reminder for big businesses to pay small enterprises on time. “Small businesses are impacted by late payments in a big way and they’re often in a power imbalance with larger clients, which is…

  • Contains:
  • Medical Health Aged Care
  • 31/10/2024
  • 12:10
MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study,…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.